Intranasal Ketorolac (Sprix)
An intranasal formulation of ketorolac tromethamine
(Sprix – Lutipold) has been approved by the FDA for
short-term (up to 5 days) treatment of moderate to moderately
severe pain in adults. It is the first nonsteroidal
anti-inflammatory drug (NSAID) to become available in
an intranasal formulation. Ketorolac tromethamine is
also available in oral, ophthalmic and injectable formulations....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Intranasal Ketorolac (Sprix)
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1382
Article Code: 1382d
Date: January 23, 2012
Volume: 54
Pages: 7-8
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1382
Article Code: 1382d
Date: January 23, 2012
Volume: 54
Pages: 7-8
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)